Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 11.59%
- Poor long term growth as Net Sales has grown by an annual rate of 0.84% and Operating profit at 5.71% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
ILS 115,564 Million ()
12.00
NA
0.00%
1.69
40.69%
4.58
Revenue and Profits:
Net Sales:
15,366 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,561 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.87%
0%
-7.87%
6 Months
52.0%
0%
52.0%
1 Year
58.13%
0%
58.13%
2 Years
88.91%
0%
88.91%
3 Years
195.86%
0%
195.86%
4 Years
252.18%
0%
252.18%
5 Years
143.24%
0%
143.24%
Teva Pharmaceutical Industries Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.84%
EBIT Growth (5y)
5.71%
EBIT to Interest (avg)
3.23
Debt to EBITDA (avg)
4.44
Net Debt to Equity (avg)
2.39
Sales to Capital Employed (avg)
0.67
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
11.59%
ROE (avg)
25.11%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
4.93
EV to EBIT
12.30
EV to EBITDA
9.79
EV to Capital Employed
2.46
EV to Sales
2.81
PEG Ratio
0.24
Dividend Yield
NA
ROCE (Latest)
20.01%
ROE (Latest)
40.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
15,366.40
15,032.50
2.22%
Operating Profit (PBDIT) excl Other Income
5,014.80
4,421.30
13.42%
Interest
702.50
796.80
-11.83%
Exceptional Items
-3,196.90
-588.40
-443.32%
Consolidate Net Profit
1,561.00
1,459.20
6.98%
Operating Profit Margin (Excl OI)
271.30%
238.40%
3.29%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 2.22% vs -0.22% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 6.98% vs 44.52% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
59,751.00
61,114.70
-2.23%
Operating Profit (PBDIT) excl Other Income
17,311.70
16,243.00
6.58%
Interest
3,245.70
3,483.30
-6.82%
Exceptional Items
-6,494.90
-13,944.20
53.42%
Consolidate Net Profit
4,891.00
-7,251.60
167.45%
Operating Profit Margin (Excl OI)
231.90%
201.60%
3.03%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.23% vs 4.56% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 167.45% vs -219.72% in Dec 2024






